Ran is overexpressed in breast and lung cancers and knockdown of Ran leads to a reduction of Met receptor expression that contributes drug resistance of trastuzumab and gefitinib249 [Fig. 4], (Table 1). The gene discussed is RAN; the disease is lung carcinoma.